BRAF and metastatic melanoma: Even though the optimal sequence of targeted therapy and immunotherapy for the treatment of patients with BRAF-mutated melanoma is still under investigation in clinical trials [DREAMseq (NCT02224781) and SECOMBIT (NCT02631447)], currently the American Society of Clinical Oncology and the European Society of Medical Oncology guidelines recommend both therapies as first-line treatment for metastatic melanoma (140, 141).